-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JksE8+Q9/WHSQzEwLWf7EV89TNybYckGkEF8udNy9XDqgLTvavAc9/LsAHeM9aPn
 mYr3VHlis2Nn2QQm0rkpPg==

<SEC-DOCUMENT>0001178913-08-001474.txt : 20080611
<SEC-HEADER>0001178913-08-001474.hdr.sgml : 20080611
<ACCEPTANCE-DATETIME>20080611070224
ACCESSION NUMBER:		0001178913-08-001474
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20080611
FILED AS OF DATE:		20080611
DATE AS OF CHANGE:		20080611

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30902
		FILM NUMBER:		08892169

	BUSINESS ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		72 PINCHAS ROSEN ST
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			69512
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk85394.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\office\EDGAR Filing\Compugen Ltd\85394\a85394.eep       -->
     <!-- Control Number: 85394                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="4"><B>FORM 6-K</B> </FONT> <BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE="4"><B>SECURITIES AND EXCHANGE COMMISSION</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Washington, D.C. 20549</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>Report of Foreign Private Issuer</B> </FONT></P>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934
<BR>for the month of June 2008
</FONT></P>


<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="5"><U><B>Compugen Ltd.</B></U> </FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Translation of
registrant&#146;s name in English) </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Center Underline-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2><U>72 Pinchas Rosen
Street, Tel-Aviv 69512, Israel </U></FONT><BR>
<FONT FACE="Times New Roman, Times, Serif" SIZE=2>(Address of principal
executive offices) </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Minor Center-TNR" FSL="Workstation" -->
<P ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2> Form 20-F <FONT size="3" face="Wingdings">x
</font> Form 40-F <FONT size="3" face="Wingdings">o
</font> </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On Jun 11, 2008 Compugen Ltd. (the
&#147;Registrant&#148;) issued a Press Release, filed as Exhibit 1 to this Report on Form
6-K, which is hereby incorporated by reference herein. </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Major Center Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>SIGNATURE</U> </FONT> </H1>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized. </FONT></P>

<!-- MARKER FORMAT-SHEET="Signature (Single)" FSL="Workstation" -->
<TABLE WIDTH=100% CELLSPACING=0 CELLPADDING=0 BORDER=0>
<TR VALIGN=TOP>
<TD WIDTH=40%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=10%><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
<TD WIDTH=50%><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Compugen Ltd.<BR>(Registrant)<BR>
<BR>By: /s/ Ronit Lerner<BR>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;<BR>
Ronit Lerner<BR>Date: Jun 11, 2008</FONT></TD>
</TR>
</TABLE>
<BR>


<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_1.htm
<TEXT>
<HTML>
<HEAD>
     <!-- Created by EDGAR Ease Plus (EDGAR Ease+) -->
     <!-- Project:        \\Backup\office\EDGAR Filing\Compugen Ltd\85394\a85394.eep       -->
     <!-- Control Number: 85394                                                            -->
     <!-- Rev Number:     1                                                                -->
     <!-- Client Name:    Compugen Ltd                                                     -->
     <!-- Project Name:   6-K                                                              -->
     <!-- Firm Name:      Zadok-Keinan Ltd                                                 -->
     <TITLE>6-K</TITLE>
</HEAD>
<BODY>

<!-- MARKER FORMAT-SHEET="Scotch Rule Top-TNR" FSL="Workstation" -->
<HR ALIGN=LEFT WIDTH=100% SIZE=4 NOSHADE STYLE="margin-top: -5px">
<HR ALIGN=LEFT WIDTH=100% SIZE=1 NOSHADE STYLE="margin-top: -10px">


<!-- MARKER FORMAT-SHEET="Head Major Left Bold-TNR" FSL="Workstation" -->
<H1 ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><U>Exhibit 1</U> </FONT> </H1>

<P align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><IMG SRC="compugen.jpg"></FONT></P>

<!-- MARKER FORMAT-SHEET="Head Left-TNR" FSL="Workstation" -->
<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>For Immediate Release </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 1 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE="3"><B>Compugen Announces Discovery of Novel Drug Targets for Cancer <BR>Antibody Therapeutics</B> </FONT></P>

<!-- MARKER FORMAT-SHEET="Head Sub 2 Left-TNR" FSL="Workstation" -->
<P ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Further
Experimental Validation of Therapeutic Potential Now Underway</FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Tel Aviv, Israel &#150; June 11, 2008
&#150; Compugen Ltd. (NASDAQ: CGEN) announced today the discovery of more than ten novel
targets of antibody therapy for various types of solid and hematopoietic cancer. The newly
identified targets were initially predicted and selected <I>in silico</I> utilizing the
Company&#146;s Monoclonal Antibody Therapeutic Targets Platform and subsequently were
experimentally validated. In addition, the Company announced that further experimental
validation of the therapeutic potential has been initiated for five of these targets. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This group of novel targets offers
the opportunity for advancing the development of antibody biotherapeutics for a wide range
of oncologic diseases, such as ovarian cancer, lung cancer, colon cancer, multiple
myeloma, acute and chronic leukemia and Non Hodgkin lymphoma. All of the new targets are
membrane bound molecules which have been shown to display differential RNA expression in
various tumor vs. healthy samples. In addition, a number of them are splice variant
molecules, the existence of which had initially been predicted by the Company&#146;s LEADS
platform. This class of molecules would be particularly difficult to find utilizing
traditional discovery methodologies. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Anat Cohen-Dayag, Ph.D.,
Compugen&#146;s Vice President of Diagnostic Biomarkers and Drug Targets stated,
&#147;Monoclonal antibody therapeutics is the fastest growing segment of the
pharmaceutical industry with the potential for yielding improved therapeutics to treat
many life-threatening and debilitating diseases. Furthermore, with a typically faster
discovery to development to commercialization process and a higher probability of success
in human clinical trials, this segment has become a major focus of the industry.
Therefore, we see our unique Monoclonal Antibody Therapeutic Targets Platform as an
extremely valuable asset of the company and are very pleased by its continuing and growing
success in identifying novel targets of interest. We look forward to continuing use of
this platform both in our own discovery activities and in collaboration with
partners.&#148; </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>About Monoclonal Antibody (mAb)
Therapeutics: </B>Over the past two decades, monoclonal antibodies have emerged as an
important and rapidly growing new drug class. Monoclonal antibodies have the ability to
target specific cells of interest &#151; such as cancer cells &#150; and can be utilized
to stimulate the patient&#146;s immune system to attack such cells, to deliver a toxin
locally to the cells, or to block specific cell receptors. To date, mAbs have been
approved for therapeutic use in oncology, transplantation, chronic inflammatory,
infectious and cardiovascular diseases. Although significant progress has been made in
recent years, one of the key challenges in the mAb therapeutics field remains the
identification and validation of novel targets. </FONT></P>

<p align=center>
<font size=2></font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
<page>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2><B>About Compugen&#146;s Monoclonal
Antibody Therapeutic Targets</B> <B>Platform</B>: This Platform relies on Compugen&#146;s
LEADS and MED infrastructure platforms, protein domain predictions and other public and
proprietary data sources to predict novel membrane proteins that can serve as targets for
antibody therapeutics, such as for various cancer and autoimmune diseases. The selection
of appropriate candidates from this large body of predicted membrane proteins is
accomplished using sub-modules of algorithms and other computational tools developed
specifically for the disease state or protein family of interest. The selected candidates
are then experimentally validated. </FONT></P>


<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Workstation" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B>About Compugen </B><BR>Compugen&#146;s mission is to be the
world leader in the discovery and licensing of product candidates to the drug and
diagnostic industries under milestone and revenue sharing agreements. The Company&#146;s
increasing inventory of powerful and proprietary discovery platforms is enabling the
predictive discovery &#150; field after field &#150; of numerous therapeutic and
diagnostic product candidates. These discovery platforms are based on the Company&#146;s
decade-long focus on the predictive understanding of important biological phenomena at the
molecular level. Compugen&#146;s current collaborations include Biosite, Medarex, Inc.,
Merck &amp; Co., Inc., Ortho-Clinical Diagnostics (a Johnson &amp; Johnson company),
Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. In 2002,
Compugen established an affiliate &#150; Evogene Ltd. (TASE: EVGN.TA) &#150; to utilize
the Company&#146;s <I>in-silico</I> predictive discovery capabilities in the agricultural
biotechnology field. For additional information, please visit Compugen&#146;s corporate
Website at <U>www.cgen.com</U> and Evogene&#146;s corporate Website at
<U>www.evogene.com</U>. </FONT> </P>

<!-- MARKER FORMAT-SHEET="Para Flush Lv 0-TNR" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>This press release may contain
&#147;forward-looking statements&#148; within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include words such as &#147;may&#148;,
&#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, and
&#147;intends&#148;, and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially different from any
future results, performance or achievements expressed or implied by such forward-looking
statements. Some of these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks relating to the
development of new products; and the ability to implement technological improvements.
These and other factors are identified and more fully explained under the heading
&#147;Risk Factors&#148; in Compugen&#146;s annual reports filed with the Securities and
Exchange Commission. </FONT></P>


<P ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE="2"><B><I>Company contact:
</I></B><BR>Marjie Hadad
<BR>Media Liaison
<BR>Compugen Ltd.
<BR>Email: marjie@netvision.net.il
<BR>Tel: +972-54-536-5220 </FONT>
</P>


<p align=center>
<font size=2>2</font></p>
<HR SIZE="1" NOSHADE  STYLE="margin-top: -2px">
<HR SIZE="4" NOSHADE  STYLE="margin-top: -10px">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>compugen.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 compugen.jpg
M_]C_X``02D9)1@`!``$`E@"6``#__@`?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$``0"`P,#`@0#`P,$!`0$!@H&!@4%!@P)"0<*#PT/#PX-
M#@X0$A<4$!$6$0X.%!P5%A@9&AL:$!0='QT:'Q<:&AD!!`0$!@4&#`8&#!D1
M#A$9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9&1D9
M&1D9&1D9&?_$`:(```$%`0$!`0$!```````````!`@,$!08'"`D*"P$``P$!
M`0$!`0$!`0````````$"`P0%!@<("0H+$``"`0,#`@0#!04$!````7T!`@,`
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1``(!`@0$`P0'!00$``$"=P`!`@,1
M!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_``!$(`&L!``,!$0`"$0$#$0'_V@`,
M`P$``A$#$0`_`/OZ@`H`*`"@`H`0G`H`H76NZ-:W#P7&K6$,L9PT<EPBLI]P
M3Q5*$FKI`1_\))X?_P"@YIG_`(%1_P"-/V4^S`/^$D\/_P#0<TS_`,"H_P#&
MCV4^S`JZQXW\&Z19F[U7Q;H5A;@X,UU?Q1IGTRS`54,/5F[1BW\@-FQN;>\L
MXKNTFCF@G021RQME74C(((Z@BLFK.P$M`!0`4`%`!0`4`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`$5U,(;=Y=COL4MLC7+-@=`.YI;@>5:E
M\5?%LC3VR?`OQM/;MN0/YEO&77IG'F97(_&O2C@:>C]M'\?\A'FMQX7\#SSO
M/<?L;7\TLK%WEE@LV=V/4DF3))]37I1KXB*M'%V7J_\`(FR[#/\`A$O`(_YL
MPNA_VZV7_P`73^LXG_H,_&0:=C'\9>%]$.ANG@_]C?3$U-B`DFKPVOD1CN2L
M;[F/L"OUK6CB*O-^^Q;MY-W_`!#;9'3?LQ?"`:K<7&M_$?X)?#CPZEI*GV"W
ML-'*W#NI#>:6:9U"@XP,9)R>,<\V99BX6AAZ\Y7WN]/0<;]3Z810@PHP!7SY
M0M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`8'Q
M`\;>$O`^F0:CXO\`$.GZ):7,OD137LPC5Y,%MHSU.%)_"M:.'JUI<M*+;\@/
M!/%/C#X?ZUXAN]33]KZ]TN.X<LECIUS91P6Z]E0&(G`]6))[FO;HX:O3@H_5
M;^;YO\R?F4/[<\`?]'HZ]_X'6/\`\9K3V5?_`*`U]TO\Q?,/[<\`?]'HZ[_X
M'6/_`,9I^RK_`/0&ONE_F'S/./&?Q,\$ZC'J'AZ_^,'QKUG36<PO);P6`@NT
M!ZJ3M8H?<#(]C7?1P-56J*C33\W*Z_&Q+DC`^'GA#X(^-_'&F>$=+UOXM+=:
MO-Y*M)#8QH@P2Q+*Q*C`/(!(K?$XC&8>FZLHPLO\0HI-VU/T%T6PL]*TFUTS
M3[:.VM+*);>"",86.-0%50/0``5\))N3YI;FVQ:H`*`"@`H`*`"@`H`*`"@`
MH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`/2@#@?BBGQ-EUV"/PCX4\#:OI
MJ0AC+X@U&>"9)22&"HEO(-NW;SG)R>..>O#>P2;JRDGY+_@H3OT.:^R_'3_H
MFOPB_P#!S=?_`"%73S83_GY/[E_\D+W@^R_'3_HFWPB_\'-U_P#(5'-A/^?D
M_N7_`,D'O&'\2+/X]_\`"#:B]OH'PC\*M"BS-K(U69Q:1HP:1B)+$K@HK*2>
M@;/:MJ$L$JBYI3EY66O_`),+WCR#^T/C=_T7'X*_^#2#_P"0:];V6#_Y\U/N
M?_R1/O\`D=!\*O$GQ*T3XA:7JGC#XQ_""]T&WD)O8+35H1*8RI!*8LT.1UQN
M&<=:Y\70P\Z3C1HU%+I=:?FQKF3U/KFSGAN;6.XMI4EAF4/')&P974C(((Z@
MBOE[6T9H2T`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`
M%`!0`4`<Y\2_!6B>.="CTG7/MR0PS+/')8WDMK*C@$</&P.""00>#GZ5M0Q$
MZ$N:'XI/\PL>#>/O"/PJ\(>)'T;4=$^--W(B+(MQI<FJ7D$BGNLD3,/J#@CT
MKV:%?$UH\T907KRI_B0TD8OD?!K_`*%GX_?^`>MUM;%_S4_O@+0;+:_!:2)X
MI?"OQ[DCD4J\<ECK3*RD8((/!!'8TU]<6JG3^^`:'"^.O#GPPLKR`>#O@-X_
MUFV=/WOVVQU.TDB8'C&8B&!'H<BNVC5Q4D_:UXQ]'%_J)I=$8?\`8^@C_FU_
MQG_WWJ/_`,9K?FJK_F*C_P"2_P"8M/Y3U7X(?&+Q!X"L[3PW#\"O']MX<2;Y
MOW%[=R6:'KY2O$/E!YV`],X["O+QF6PK-U/;Q<O5*_XE*36ECZSL+B.ZLXKF
M$L8YD612R%3@C(R#@CZ'FOF;6=C0FH`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`"@`H`K:M%=2:9<16%R+:Y>-EBF9-XC<CY6*]\'
M'%-63NPN>*B7XWQ_)-\9/ADLB?*X_LUAAAUX\[CFO7_V+_GU/[_^`(//^-?_
M`$67X9?^"YO_`(]1_L7_`#ZG]_\`P`#S_C7_`-%E^&7_`(+F_P#CU'^Q?\^I
M_?\`\`#PKXMZ-K_A?Q0W_"0?M-W5C-JI>\2VTJ;4YH(P6Y"[)VV#).%)X'3B
MO9PE2E4A:EAKI=^6_P"*,Y:=3EQJ!_Z.I\0?]^]8_P#CE=7*MOJJ_P#)?\B;
MK^8^J/V%]2>_^$NI0-\09_&RZ?K$L"ZC<0SI)$&BAE\IC,2[X,I8'.`'"C[M
M?,YQ!0KZ4^2Z6FGZ&L=M#VBO**"@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*
M`"@`H`*`"@`H`*`"@`H`*`,#XC:Y?^'_``XU[I?AC4?$5T9%C6PL&17(/5BS
MD``#W]*UH4XU)\LI**[L-CY]F\(^#I9GFE_8TE>21B[NZ6)+$G))._DYKWE7
MK15HXS3UD3\AO_"&^"_^C,&_[]V/_P`73^LU_P#H,_&0QDOA+P-"FZ;]C58E
MZ;I!8*/S+T_K%?IC/QD!POB/POXO'B"[;PI^S-\.[#1V8?9H+ZW@DG"@#)=D
MN%7).>`.!CDUV4Z]+D7ML3-R\F[?*Z);ET12_P"$7^*3$)'^SI\,7=ONHE@A
M+'T`%U5>WPJU^L3^]_Y"][L?7_P.\*+X.^&VGZ3)I&B:7?.OVB^@T2V,%K]H
M?ERBEF/H,DG./PKY7%U_;57*[:Z7U=C0ZZN8`H`*`"@`H`*`"@`H`*`"@`H`
M*`"@`H`*`"@`H`*`"@`H`*`"@`Z4;`<C\0OBA\/O`MU%;>+O%^E:1-.,I%<S
M`.1Z[1R!]:Z*&#KXC^%%L+I'#>-/CO\`"+6-$>PTGXWZ7H$TA&Z^LQ'),B^B
M"5&0'IR5;^H[J>4XN$KRHM^7_#"YD>>#Q/\`#8#_`)/-\6_^!-C_`/(E=WU;
M$_\`0)'[I?\`R1%O,/\`A)_AM_T>;XM_\";'_P"1*/JV)_Z!(_=+_P"2#YG&
M>*/B]X7TO57M--^.7QHUN*/@W=G'IRQ,?]DO;@L/?&*ZZ.759J\J-./D^;_Y
M(3=NIQWCOQI\./&L<$7BWQK\:]8BM26BBNFTTHC'N%$0&??&:Z\/A<3A[NE"
MFG_V]^K%==V7_A#\'OAQ\2=66U\,:?\`%EK8-MFU*XCTR.V@]<N8N3[+DU&+
MS'$82/[QT[]O>O\`F-03V/J3]G_]GCP%\)]2GU?2Q>ZMK$V574M5,;201_W(
MA&B*@/<XW'N<8`^;QV;5\8E&5E%=%_P6V7&*B>MUYA04`%`!0`4`%`!0`4`%
M`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`A(%`'%_$K4/BG;ZI!#X!\-^%=0M/
M+W37&M:O-;-OR?E5(X).``#DGOC'&:Z</'#M-UI->B3_`#:$[]#D9F^/LMPT
M\WPY^%$DKX#2/KET6..F2;.NI?4EHIS^Y?\`R0O>&_\`%^O^B;_";_P=W7_R
M'1?!?SS^Y?\`R0>\8/CCQI\2_!T=N?%>@_`_0C>[UMCJ/B.XB$I4#=MS:#=C
M<N<>H]:WH8>A7=J3J.V]HK_,/>/&;[Q)\5KJ\DN#^T+\(;<R,6\FUUB*.)/9
M5^RD@#W)/J2>:]F-#"Q5OJ]3YI__`"1+OW+'AMOC9X@UN#1M`^._PUU34;G)
MBM+/5HY)'P,G"BSST!J:GU*C'FJ4)I>:?_R0*_1GT%\"_AAXZTGR]5^)OCN3
M7+W!QI5I#$EG$3W9Q&KRGZ[5Y^Z<`UX.-QE&?NX:'*N[>O\`DBXIVU/6K6V@
MMH1%;PQQ(O(6-0H_(5YCUW&2CB@`H`*`"@`H`*`"@`H`*`"@`H`*`"@`H`*`
M"@`H`*`"@`H`*`"@`H`1NG%)@?)_B"+X-/XAU%[SPA\;FN6O)FF:"'4S&9#(
MVXIM?;MSG&.,8QQ7TE*>*4$HSIVMUY;_`(DZ%3R/@E_T)WQT_P"_.J__`!=:
M<^+_`)Z?WP#0/(^"7_0G?'3_`+\ZK_\`%T<^+_GI_?`-#B_B78^$+C5[5?"W
MP3^(?B*RBA):;7+C589(9&;YE12&^4A4.0>2/:NO#3JI-U:T(ORY61*VUC`M
MM!@N+J&V@_9GU\RW$BQ1A]3U)%+,0HRQ0!1DCDG`K>5?E3?UE?='_,5E_*?9
MWP(^$WA+X;:0\NBZ%;V.J7\:?;I4N)+@[@.4223YM@.<#C/7%?)8S'U<4_WC
MNEMT_!&J26QC?'']H?P!\,]3.BWDMYJ^MJ`7TW2T5V@!&0978A$[<9+8.0I%
M;8+*<1BES15H]WH$I*)YC9?MKZ,UV%NOA]J:6X.&:"_BDD`]E(49^K#ZUZ4N
M&JJ6DU^)'M$?0/PH\>>'?B)X'MO%7AF[>:RG)1TF3RY;>1?OQR*?NLIZ]0>"
M"003X6(PU3#5'2J*S1HFF>4_%']K/X=^%M:GT?0[;4/%%U:DI+/8;$M$<'!3
MSG/SD>J*R]LY!%>GALAQ-:*G*T4^^_W$N:1SF@?MI^&);Y$USP3K.GVC'#7%
MI.ET4']XIA20/]G)]`:Z)\-UDO<FF^VQ*J(]N\8?$SPQH7P:G^)L=P^J:%%:
MK=Q26&TM<HQ`4)N*C))`P2*\:CA*E2NL/:TKVU+NDKGE&@?MA_#[4]=L]-D\
M/>)-/2ZE$;WEZMJD-NO\4CD3$A5&2<`GC@$UZE3A_$0@Y\R?DK_Y$JHC)U;]
MM/PO%K+1Z7X(UN]TU7P+N6:."61<_>6)LD9Z@,5/J%/36'#=9QO*:3["]HC>
M^('[6_P]T/2].FT&TU#Q!>:C;)=&UA"PBT5OX)G;(63((VJ&(QS@$$X8?(,1
M4DU)J*6GKZ>0W-+8Z;]F[X]Z!\7+R^TJWTF\T?5[",3O:7#K(DD1.W<CKUP>
M""`1D=:YLPRNI@DI-W3Z^8XR3.0\0?MA^`=*\0ZEI!\,>*KIM-O)[)I[>.V,
M<IBD:,NF9@2I*$@D#((KKH\/8BI",^9*ZOKY_(7.BGXJ_;+\&V1MDT#PMK&K
M.\*2W!EDCMT@=E#&+/S%W4DJQ`VY'#-SBZ7#M>=^>2B)U$MCT_X"?&;PS\4_
M"M_JNE0W5A<Z.0+^PNPOF0`J2K@J2&1@K;6']U@0""!YN.R^K@YJ$];[,J,D
MU='F,_[:?P^C\S;X0\7R",L`5BM?GP<<9G[UZ2X;Q#^U'[W_`)"]HCM?C'^T
M/X8^&RZ"NMZ!K]Q/KUB+](+1("UNAQ\LFZ11NR2.,C@\UQ8/*JN*YN1I<KMK
M_P`,-R2+OP!^.GAWXLW>L1:+HFM:9'HD44L\^IK"J'>7X!21N0$R<XX(J<=E
ME3!<O.T[]F.,D]CS_P`<?MD>"=-UA[3PKH.H^)+>)BIU!95MK>7WB+`LZ_[6
MT`]02.:[J'#U><5*HU&_3J2ZB6Q(_P"V7\/8]*L;@^'/$TES<*_VBUAB@)M6
M4@`%FD4,&SE2N>`<[2,4EP[B>9KF6GGO^'02J(]*^`WQ@T/XJ:!JFM:5I6J:
M39:3*(99-4$2!CLWD@H[#`&,DD5Y^-R^>#FH2:;?8M-,\Y^(7[87P_T35)K#
MPWI>I>)?L[%6O82MO:,1P=CO\SC/\07:1R&->AA^'L14CS3:CY:W^Y$NHEL0
M>`?VQO!FK:[;Z?XD\/:EX>ANI%B2^,J7$$9/`\PKAE!.!D*0,\X'-.OP]7IQ
M<H24K=-F$9INQZ3^T%\:/#GPBL](GUO3]3U$ZU)(D$6FK$S!44,SG>ZC;\RC
M@GEA7GX'+JF,<E3:5NY4I*)P>C?MA?#>\L]1NKK1O$FG)I\"RHD\,#27<C-M
M6&)4E)+GDDG"J`2S`<UVU.'\3!Q2:=_P\WH)31F^$/VR/#&J>++/2]6\(:II
M-E>W"6ZW_P!H281%V"JTB``A<D9*EL=<$9K2KP]6A3<XS3:5[>A*J*]CZ67I
M7SYH+0!Y)\21X^T[Q;<-#\:_"WARPNV,EG8:GIL1E1``&^9I5+@-GG'<"O1H
M/#N%I4G)]T_^`)W,'^T?'O\`T<EX!_\`!=;_`/QZMO\`9_\`GQ+[W_D+7N']
MH^/?^CDO`/\`X+K?_P"/4?[/_P`^)?>_\@U[G"?'FPUC4?#T.N^)?VEK)8-%
MWX7PO$T<S"5HU.Z."XS(`57'!*@L>A-=V!J4XSY*6'U?\VVGJM!-/N6_V'M+
MTO4_B5J6MV'Q<\5^+UT:S$;66HI=PPQ/,Q"N1+(RN=L;@#'&<^E3G,Y1I1A*
MBH7=[JW3T007F>^_''Q6?`WPA\2>+8U#3:1ITUQ!&>DDP4B-3]7*C\:\3!T/
M;UX4N[2*;LC\U]!TW4O%?C2RTE[R674_$6HQP2WA.9'EFD`>3GOR3^`K]$J3
MCAZ3DEI%;',E=ZGUM^T/\`_A[JVNZ1::/XQ\+>!(])L1;-8ND2R3C/RN^75F
M.`1N;)/.2:^3P&:UJ:DYQ<[NYM*%SB?B'H[_``1_9?U71?#WCJW\0#QOJZV_
MVS3\*D4:Q8F4%6;YB$`//3BNS#S688V,YPMR+9_@*W)$\O\`V5/!%EX[^.>B
M^'M1MQ)I<(>[O(1PKQ1KD(<=BQ4''K7JYKB98?#2G%ZZ)$4XZZE#]H:VT.Q^
M.OBNQ\-645EI5I?F"WMX?N(415?;[&0.?QJ\M<WA8.H[NWZZ"DM6=SXHUB[T
MO_@G_P"%O#\DA'_"1>))F2)CS]DA>28L/]GSDB'_``,>M<-*G&>:3FOLQ_%V
M7Y7*?P&#^R+X(TGQ]\<+72?$%H+K1["RGU&\MRQ42*FU5!(YQOD0X]JWS;$S
MPN'YJ;M)NR_,5-)O4\WU6YL)M0OKS3(_+T^2>:6T3.[;`78QC/?Y-M>E34N5
M*>^E_4E^1ZE^TAX*\.>!/"/P\TW3]/6'7=1TDZAJMSO8F9FVXR"<#!+`8`X%
M>7EN)J8BI5G)^ZG9%SBDE8Z?]@P+HEWX]^(,VU8O#NAL$9NF\[I/Y(!7-GKY
M_9X=;M_\`JFK:G@-M!>7IAM+7#7U](D$.[D&61@JY_X$PS7O7C!7Z+]#+<]O
M_;?\#>#?AWK/@KP[X5T^.UN_[,GEU*0.6><AH4B>3)ZDB?!&.C>V/&R3$UL1
M&I.J[JZM^-_T+J*UBA^S)J]WX8^&/Q>\3VS*/LN@PVL8+8W3RO*L8_G3S2"J
MUJ%)]9/[M`@[)L\V^&VAMKOCSP_X<B`;[??V]K@]P74'/X9KT\35]E2G4?1,
MF.YZ9^W=K::K^T;J%E`P-OH5I!8(`>`0N]A^!?'X5YN1T>3"*3ZMLJIN,T:_
MN/"'[$NI/:2-#=?$'7C8R.G!-I%'^\&?1@FP^SFE."K9BD]J<;_,<;J&AS_[
M+?@BS^(/QST;P[JD32:6GF7E[$I(\V*,9$9(Y`9BH..V1WKIS3%2PV&E.&CV
M1--)LK?M(6'A_2OCSXITGPK8QV6E6%VMM%;Q$[4=8T$F,_\`33?59;*<L+"5
M1W;%/?0['7]5OO"?[#7A?0;626VE\?:E=ZA=E3C?:I(50`C^%T2$GV)%<=.G
M&MF4ZC^PDEZV_1W+=XPL>?\`PBOKO2/%G]LVGP_;QG]BC(^Q-8374,+M]UW6
M)6]&P&X//I7?C(J=/D=3DOUNE?[R87WL0^,-#\6ZQK>I:I!\,_$6F1WTKS+8
MV>@7@A@W<[$!CX7T%.E5HTXJ+JIVZN2_S#E=[V/0OVUM4O9O&?A'PW>2L[>'
M/#-M'*C@ADN)OFE!S_L1P?K7GY+32IU*J^U+\%_PXZNZ*GPG\&>&)?V9/B3\
M1O$VG_:KC3(QIVCLSLHBN7"JC#'4F66)><]#6F+Q558RCAZ3M?5_UZ!&*Y;L
M\_\`ASH[^(/B/X;T"/KJ6JVMN3_LF5=Y_P"^0U=^*J*G0G-]$R(J[2/U+7I7
MYJ=0M`''_&'PEX<\0>'WU#5OAWHWC.^TR-GLK'4+>%F9CC*H\H(3./H<"NG#
M8BK1E:G4<$][-_H#/&AX:T[_`*,KT3\]+_PKU_;S_P"@Q_\`DQ.O87_A&M._
MZ,KT3\]+_P`*7UB?_08__)PN^PJ>&[!&#+^Q;HJD="K:6"/TH]O/_H,?_DPM
M>QT'[)6A^-]$\3>)!XF^&WA[PCI]TL+63Z3:6\$DVUY/DF,1(8JK#!Z<MCK7
M/F=2C.,/9U')K>[;^ZXXJW0])^-O@Y/'_P`*/$'@YI_LS:O9/!%.1D12]8W(
M[@.%)'?%<&$Q#PU:-9=&4UI8^!C\//C!\.?'=CJ?_""ZP=1T:[2YM[BSLVN[
M=W4\$&/.5/O@\U]O]<P>*I./.DFMF[,YU!QU1LM\*/C9\9?B'=^(=:\,7%G=
MZFZ^=J.L0?9H($`VJ%0_/M4#A0.>>><UE''X/`4E3IRNET75^H<LI.[/H3XR
M?LZK<?LSZ)X#\%21F_\`"TGVN!IP(Q?2MN\XMCA6<NQ'8'`KP,%F[CBY5Z^T
MM'Y=ON-91TLCYE\(:)\;?AGXQ;4M#\&^)M.U4PO;&1-+:Y0HW7E0R]@0<\$"
MOI:U7!8NGRSFFO6QDE*.QT'PE_9N^)?C?7DN/$>GWGAW2YI3)=WVHX%S)DY;
M9'G.XY/+8`Z^U<V*SC#X>/+2?,TK*VPU3;>IWW[;'PZ\67VL^#O"OP_\"ZK>
M^'O"VDM!";*)3'&SLHVY+#D+$F?K7%DN,I152K7FE*3Z_/\`S+G'30J?LS_#
MWXA^"OAA\4_$5SX/U>UU^^TI-,T>R:-1.[E9"73#8QNECSR/]559EC,/7KT:
M:FN5.[?3I_D*$6DSR?PK\"_BA<Z_H^DWGP^UVQL+B]MK6>YDB39;P-*B22'#
M=%0LWX5ZE?-,-&$I1J)NSMZVT(4'<](_;*\"_$OQ?^T%J.H:'X"UR]TFRM+>
MRM9X(T,;A5+,5RPXR^.G\-<&3XO#4,*HSFDVVV7.+>PL6BZ[\,/V%O%">(-(
MN])U?Q7J\=B+>Y`5UCRHR<$\%4D_.I=2&+S*'LW>,4%N6.IXA\/-!\1>(_&%
MIIGA."276$)NK58W"L&B^<%2>,\#&>M>WB:M.E3<JNW^>AE%.^AUWB'PI\<?
MB9X_>^USPEXDO]:G5(&FO+(VT,*+D!0Q`15!)/&>23R37'3Q&"PE/EIS2COH
M[LMQDV>_>*/@!K7AG]C+4_!OAY1J?B6]O8=7U%83C[7(K)F*//94C4*#U*YZ
ML:\.GFL*N81K5-(I67EY_>S3EM&R/GSX6?#?XPOX_P!/D\,>$M>TG5;*X$D>
MH7MF88K5A_$S2#:1@G@;L]*][%8W!^Q:J333Z)ZLRC%WT#Q-\)/C1=^(M3O;
M[P+XCU2[GN9'FOC$G^E-N/[SENC8!'MBG1S'!1A%1FHJVVN@W"5]3W_Q_P#`
MZ^UC]D?P;X9MYK&P\4Z#&M^MM>2+%YK2`^="2?NM\PYZ;D&?4?/T,U5/'5*L
MM82T_P`F6X^[8\>^&7P8^/-AXL2Z\-6DWARY3,,FJIJ$(2&-OO9*ELC'.,9X
MXP>:]C$9G@)T[5'S>5B(PDCQQVDO$=K&>2[ENW/D3L69KAG;Y7)/)+$AN>>>
M>:]=6@O>5DOP\B=V?:?[4WP-UO7?@AX,TWP?;+<WW@FSCM%T_<%,\(B1"$)X
MW#8#@]>:^.RS,X4L3.=9Z3=[]G>YM.-T>!_"R[^._P`,GUK3O"G@KQ%:3:W&
MD5R9-%ED9"FX*R/C:&&]N<D<^U>YBHX#%<LJLU[M^IG%2BK(]+_9N^$GQRUO
MQC8ZQX]\8^/-%T*RD6>2TN_$EX9[T@Y";!,0JYQG/;@#FO.S',,'"FX4(1<G
MUY59?@7%2W9Q/[17P]^*WBSXY>)]?M/AYXAN;2XO"EO,L28>)`$4C+="%XKN
MR[&86AAH0=1)_P"9,XML[+Q5\._'^E_L-^'/`^E>$]7NM6UC6/[1U6QAC4O`
M@=YE63YL<2+#CD_=KAHXRA+,I5I22BE9/Y6_S&XM1L9'['/PB\=Z?^T-HVM>
M*?!^J:1IVCP7%V)[R-0CR[/*1!ACS^]9A_N5OF^84)85TZ,TV[;??^@H1:>I
M]OKT%?&HV8M,`([4`)M%+E2'<,#WHL@N&![T607`#%%A"TP$P/>E8=PP*+"%
MQQBG:P"8^HI6``,4]@`CBE8`VCWHL`;1[TPV`J/<4K`>&_ML?#7QQ\3=$T'2
M?"45DT%E<R7-R;JX\O)V[4`&.>I->QDV-HX2<IU;[6T(G&ZLCD?V//@%XT^'
MWQ6N/$WB^+3T@BT]X+7[+<^8WFNRYR,=-H-=F;9M1Q-%4Z5]];BA#E/J#;]:
M^;L:+0,4P#;]:`#;]:5@/G_]M3X":C\5Y])U_P`/36/]JZ5"]LUK?#"3Q%@P
MVO@[6!SUX(/;'/N9/FBP7-3J7Y7V)G&^QX%HO[.GQ\TBPU#2='TU],L=73R;
M^"RU988;M,$;954C>N"00>H)!X)%>[/-\#-J<W=K:ZO8S49H]8_9K_98O/#G
MC"R\6_$"]M+B?2Y1/9Z5:9>,2C[LDCG[VWJ%`QD`YX%>5F.>*M3=&@K)[ME0
MIVU9]2X`KYNQH&*+`M```HL`;?<T6`,"BP`%QZT6`6GL`4`%`!0`4`%`!0`4
M`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`!0`4`%`'
"_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
